Speakers:
- Jennifer Schneider, Chief Executive Officer, Centauri Therapeutics (UK)
- Rida Mourtada, Chief Executive Officer, Lytic Therapeutics (USA)
- Gregorio Iraola, Chief Executive Officer, Kinzbio (Uruguay)
Moderator:
- Sina Gerbach, Deputy Head and Development Lead of the Transfer Group Anti-infectives, Leibniz Institute of Natural Product Research and Infection Biology (Leibniz-HKI) and Program Manager at INCATE (Germany)
This webinar featured presentations on the ongoing development of three non-traditional antimicrobials as potential solutions to combat infections.
Presentation 1: Immune therapy for infectious disease (Jennifer Schneider)
- Role of the host in the success of antimicrobial treatment
- Opportunities to address infections in vulnerable patients
Presentation 2: Development of stapled antimicrobial peptides to treat MDR Gram-negative pathogens (Rida Mourtada)
- Antimicrobial peptides: An untapped resource of non-traditional antimicrobials
- Peptide stapling to generate highly selective antimicrobial peptides that target Gram-negative bacteria
- Lytica’s success in generating StAMPs that can be administered systemically to treat pneumonia
Presentation 3: Preventing the spread of ESKAPE pathogens in the built-environment using jumbo bacteriophages (Gregorio Iraola)
- Jumbo bacteriophages are phages with expanded genomes allowing them interesting biological properties
- Kinzbio’s use of a proprietary jumbo phage pipeline to create a preventive technology aiming to cut the spread of EKSAPE pathogens through the built-environment
- Applying this approach in Intensive Care Units shows the decrease of circulating bacteria
This live webinar including an interactive Q&A session was broadcast on 22 August 2024.
If you have questions or comments, please let us know: revive@gardp.org.